Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | EIF4EBP1 | Q13541 | 8/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | XBP1 | P17861 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | DUT | P33316 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17883370 | 0.93 | L3MBTL1 (0.44) | L3MBTL1CYP1A2CYP2C19KCNH2DUT | |
| SCHEMBL16632647 | 0.91 | L3MBTL1 (0.47) | L3MBTL1CYP1A2CYP2C19EIF4EBP1FFAR1 | |
| SCHEMBL16632609 | 0.85 | L3MBTL1 (0.40) | L3MBTL1PDE3ADUT | |
| SCHEMBL14871830 | 0.83 | L3MBTL1 (0.53) | L3MBTL1CYP1A2CYP2C19EIF4EBP1XBP1 | |
| SCHEMBL16116697 | 0.83 | L3MBTL1 (0.53) | L3MBTL1CYP1A2CYP2C19EIF4EBP1XBP1 | |
| SCHEMBL14871847 | 0.83 | L3MBTL1 (0.58) | L3MBTL1CYP1A2CYP2C19EIF4EBP1FFAR1 | |
| SCHEMBL16632343 | 0.82 | L3MBTL1 (0.37) | L3MBTL1DUT | |
| SCHEMBL16632738 | 0.82 | L3MBTL1 (0.40) | L3MBTL1NPC1LMNARAB9ADUT | |
| SCHEMBL16632538 | 0.82 | L3MBTL1 (0.40) | L3MBTL1DUT | |
| SCHEMBL16632643 | 0.82 | L3MBTL1 (0.40) | L3MBTL1PDE3ADUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382245-B2 | Compounds and methods for treating HIV infections | YALE UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | POLM, POLRMT, DHFR | L3MBTL1 879/4885CYP1A2 567/4885CYP2C19 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.